×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MRK – merck & company, inc. (new) (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MRK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/2
05:56 pm
mrk
Want to work for one of America's best companies? These 3 N.J. employers made the cut. [Yahoo! Finance]
Low
Report
Want to work for one of America's best companies? These 3 N.J. employers made the cut. [Yahoo! Finance]
4/2
09:57 am
mrk
Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study [Yahoo! Finance]
Low
Report
Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study [Yahoo! Finance]
4/2
08:20 am
mrk
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration [Yahoo! Finance]
Low
Report
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration [Yahoo! Finance]
4/2
07:01 am
mrk
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS =1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens [Yahoo! Fina
Low
Report
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS =1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens [Yahoo! Fina
4/2
06:50 am
mrk
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
Low
Report
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration
4/2
06:45 am
mrk
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS =1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
Low
Report
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS =1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
4/2
06:40 am
mrk
Glioblastoma Multiforme (GBM) Treatment Market to Grow by $1.44 Billion During 2026-2030: Strategic Analysis of 23 Industry Players [Yahoo! Finance]
Low
Report
Glioblastoma Multiforme (GBM) Treatment Market to Grow by $1.44 Billion During 2026-2030: Strategic Analysis of 23 Industry Players [Yahoo! Finance]
4/2
02:13 am
mrk
Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9 [Yahoo! Finance]
Low
Report
Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9 [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
2/3/2026
06:30 am
MRK
merck & company, inc. (new)
BEAT
Report
3.0%
merck & company, inc. (new)
10/30/2025
06:30 am
MRK
merck & company, inc. (new)
BEAT
Report
2.5%
merck & company, inc. (new)
7/29/2025
06:30 am
MRK
merck & company, inc. (new)
BEAT
Report
-5.0%
merck & company, inc. (new)
4/24/2025
06:30 am
MRK
merck & company, inc. (new)
BEAT
Report
0.8%
merck & company, inc. (new)
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/1
01:47 pm
mrk
Form 4 Merck & Co., Inc. For: Mar 31 Filed by: Seidman Christine E
Low
Report
Form 4 Merck & Co., Inc. For: Mar 31 Filed by: Seidman Christine E
4/1
01:45 pm
mrk
Form 4 Merck & Co., Inc. For: Mar 31 Filed by: GLOCER THOMAS H
Low
Report
Form 4 Merck & Co., Inc. For: Mar 31 Filed by: GLOCER THOMAS H
4/1
01:43 pm
mrk
Form 4 Merck & Co., Inc. For: Mar 31 Filed by: Coe Mary Ellen
Low
Report
Form 4 Merck & Co., Inc. For: Mar 31 Filed by: Coe Mary Ellen
3/27
10:32 am
mrk
Form SCHEDULE 13G/A Merck & Co., Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Merck & Co., Inc. Filed by: VANGUARD GROUP INC
3/12
01:53 pm
mrk
Form 3 Merck & Co., Inc. For: Mar 02 Filed by: Foard Brian
Low
Report
Form 3 Merck & Co., Inc. For: Mar 02 Filed by: Foard Brian
2/24
04:16 pm
mrk
Form 10-K Merck & Co., Inc. For: Dec 31
Low
Report
Form 10-K Merck & Co., Inc. For: Dec 31
2/17
04:02 pm
mrk
Form 13F-HR Merck & Co., Inc. For: Dec 31
Low
Report
Form 13F-HR Merck & Co., Inc. For: Dec 31
2/13
04:15 pm
mrk
Form 144/A Merck & Co., Inc. Filed by: Guindo Chirfi
Low
Report
Form 144/A Merck & Co., Inc. Filed by: Guindo Chirfi
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/28
Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies
7.5%
3/25 Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response 6.5%
3/3 Form 4 Merck & Co., Inc. For: Feb 28 Filed by: Fleming Michael 6.1%
3/2 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) 5.6%
3/17 Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough 5.3%
4/1 Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic 4.2%
4/27 UPDATE 1-Neurocrine gets U.S. approval for Parkinson's therapy, COVID-19 delays launch [Reuters] 3.4%
10/28 Merck wins second chance to arbitrate rotavirus vaccine antitrust case [Reuters] 3.3%
10/3 Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates [Investor's Business Daily] 2.7%
1/31 Bristol-Myers pulls Opdivo+Yervoy lung application in Europe [Reuters] 2.3%
3/25 Merck to Donate 300,000 Masks to New Jersey for COVID-19 Emergency Response 6.5%
3/3 Form 4 Merck & Co., Inc. For: Feb 28 Filed by: Fleming Michael 6.1%
3/2 Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) 5.6%
3/17 Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant, an Investigational Treatment for Refractory or Unexplained Chronic Cough 5.3%
4/1 Medical Professionals Across Merck & Co., Inc., Pfizer Inc., and Eli Lilly and Company Activate to Support Health Systems, First Responders and Patients Amid COVID-19 Pandemic 4.2%
4/27 UPDATE 1-Neurocrine gets U.S. approval for Parkinson's therapy, COVID-19 delays launch [Reuters] 3.4%
10/28 Merck wins second chance to arbitrate rotavirus vaccine antitrust case [Reuters] 3.3%
10/3 Here Are 3 Notable Pharma Stocks That Could Top Third-Quarter Estimates [Investor's Business Daily] 2.7%
1/31 Bristol-Myers pulls Opdivo+Yervoy lung application in Europe [Reuters] 2.3%
TOP News Decliners
3/13
Trump's Coronavirus Fiscal Boost, Test Push Fuels Dow Jones Bounce [Investor's Business Daily]
-8.6%
3/20 Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer -7.0%
2/5 Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results -5.2%
4/7 Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type -4.5%
9/9 Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress -4.2%
4/21 Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts -4.2%
4/28 Q1/2020 3/31/2020 EPS 1.500 ZacksConsensus 1.390 ActVsEst 0.110 - Beat -3.8%
7/30 Form 8-K Merck & Co., Inc. For: Jul 30 -3.7%
3/6 Volatility And Pullback Presenting An Opportunity With Merck [Seeking Alpha] -3.6%
8/14 LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer -3.1%
3/20 Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer -7.0%
2/5 Merck Announces Fourth-Quarter and Full-Year 2019 Financial Results -5.2%
4/7 Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type -4.5%
9/9 Pivotal New Data from Merck’s Broad Oncology Portfolio at ESMO 2019 Congress -4.2%
4/21 Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts -4.2%
4/28 Q1/2020 3/31/2020 EPS 1.500 ZacksConsensus 1.390 ActVsEst 0.110 - Beat -3.8%
7/30 Form 8-K Merck & Co., Inc. For: Jul 30 -3.7%
3/6 Volatility And Pullback Presenting An Opportunity With Merck [Seeking Alpha] -3.6%
8/14 LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Met Primary Endpoint as First-Line Maintenance Treatment with Bevacizumab for Advanced Ovarian Cancer -3.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: